ARVN Arvinas, Inc.
USHealthcareAs of 2026-08-24
Why ARVN matters now
Arvinas, Inc. (ARVN) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.34 with -0.27% on the session and $602.6M in market capitalization; recent performance reads 1-month -10.29% and YTD -35.33%.
The latest financial table shown here is Q1 2026, with revenue of $15.6M, net income of $-57.6M, and EPS of $-0.90. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -51.9%.
The latest indexable market news headline is "Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $14.50; recent insider activity includes Cacace Angela M filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.27
P/S
5.54
EV/EBITDA
-1.92
DCF Value
$-122.08
FCF Yield
-51.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.4%
Operating Margin
-279.3%
Net Margin
-247.5%
ROE
-44.4%
ROA
-34.2%
ROIC
-46.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.6M | $-57.6M | $-0.90 |
| Q4 2025 | $9.5M | $-67.4M | $-1.04 |
| FY 2025 | $262.6M | $-80.8M | $-1.28 |
| Q3 2025 | $41.9M | $-35.1M | $-0.48 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$14.75
Target (Median)
$14.50
Target Range
$10.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.75
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.